The low-priced products are imported in parallel to the official channels of distribution established by the IPR holder (in this context the holder of a pharmaceutical patent). It is important to note that parallel imports are not counterfeits, they are original products of the patent holder sold by himself or an authorized person on a given market, and purchased and subsequently re-sold legally by a third party. Domestic marketing of the patented product will in any case exhaust the domestic exclusive using and selling rights.